1) Cummings SR, Browner WS, Bauer D, et al : Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 339 : 733─738, 1998
2) NIH consensus development panel on osteoporosis prevention, Diagnosis and Therapy. JAMA 285 : 785─795, 2001
3) Cummings SR, Karpf DB, Harris F, et al : Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112 : 281─289, 2002
4) Delmas PD, Seeman E : Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti─resorptive therapy. Bone 34 : 599─604, 2004
5) Evio S, Tiitinen A, Laitinen K, et al : Effects of alendronate and hormone replacement therapy, alone and in combinaion, on bone mass and markers of bone turnover in elderly women with osteoporosis. J Clin Endocrinol Metab 89 : 626─631, 2004
6) Writing group for the Women's Health Intiative Investigators : Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 : 321─333, 2002
7) Karas RH, Clarkson TB : Considerations in interpreting the cardiovascular effects of hormone replacement therapy observed in the WHI : timing is everything. Menopausal Med 10 : 8─12, 2003
8) Ettinger B, Black DM, Mitlak BH, et al : Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene : results from a 3─year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation(MORE)Investigators. JAMA 282 : 637─645, 1999
9) Maricic M, Adachi JD, Sarkar S, et al : Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 162 : 1140─1143, 2002
10) Lufkin EG, Wong M, Deal C : The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis. Rheum Dis Clin North Am 27 : 163─185, 2001
11) Strewler GJ : Decimal point─osteoporosis therapy at the 10─year mark. N Engl J Med 350 : 1172, 2004
12) Bone HG, Hosking D, Devogelaer JP, et al : Ten year's experience with alendronate for osteoporosis in postmenopausal women. N Engl Med 350 : 1189─1199, 2004
13) Neer RM, Arnaud CD, Zanchetta JR et al : Effect of parathyroid hormone(1─34)on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 : 1434─1441, 2001
14) Papadimitropoulos E, Wells G, Shea B, et al : Meta─analyses of therapies for postmenopausal osteoporosis VIII. Metaanalysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 23 : 560─569, 2002
15) Shiraki M, et al : Vitamin K2(menatetrenone)effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 15 : 515─521, 2000